Recruiting
Phase 1

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Sponsor:

Tanja Andrea Gruber

Code:

NCT04996160

Conditions

Acute Lymphoblastic Leukemia, Pediatric

Relapsed Acute Lymphoblastic Leukemia

Refractory Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Not accepted

Interventions

Palbociclib

Dexamethasone

Bortezomib

Doxorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information